Time |
Event |
09:00 – 11:00 |
Chemoprevention and Immunotherapy
Chairs: M. v. Knebel-Doeberitz, John Burn |
09:00 – 09:15 |
Towards a Vaccine Against MSI Cancer – M. Kloor, Magnus von Knebel Doeberitz |
09:15 – 09:30 |
Dendritic Cell Therapy with Mutant Gene Products in MSI Cancers – Gerty Schreibelt |
09:30 – 09:45 |
Development of Viral Delivery Systems for Cancer Vaccines – Elisa Scarselli |
09:45 – 10:00 |
The Role of PDL1 Inhibition in MMR Deficient Tumours – Elke Jäger |
10:00 – 10:15 |
Chemoprevention and ASS – John Burn |
10:15 – 10:30 |
Role of Environmental Modifiers in the Risk of Colorectal Cancer for Lynch Syndrome – Aung Ko Win |
10:30 – 10:38 |
OR09: Frameshift Mutations in Microsatellite Unstable Colorectal Cancers: from Immune Signature to Personalized Immunotherapy – Jean-Baptiste Latouche |
10:38 – 10:45 |
Applying Simulation Modelling in Cancer Vaccine Development – Mark Coles |
10:45 – 11:00 |
Optimizing Delivery of Cancer Vaccines: Short Peptides. Insights from Disease Modelling – Jonathan Wagg |
11:00 – 11:30 |
Coffee Break |
11:30 – 13:01 |
Polyposis Syndromes and Inherited Colorectal Cancer
Chairs: Ian Tomlinson, Ian Frayling |
11:30 – 11:45 |
PPAP and NAP – Ian Tomlinson |
11:45 – 12:00 |
Hot Topic: A New Polyposis Gene! – Stefan Aretz |
12:00 – 12:15 |
Update JPS – Robert Blatter, Karl Heinimann |
12:15 – 12:30 |
NGS Panel Testing – Gabriel Capellá |
12:30 – 12:38 |
OR04: Molecular Diagnosis of Inherited Colorectal Cancer using NGS Panel – Stéphanie Baert-Desurmont |
12:38 – 12:46 |
OR03: Functional Assays and Bioinformatics Predictions Reveal a High Contribution of Splicing Mutations in the Most Frequent Forms of Hereditary Cancer – Alexandra Martins |
12:46 – 12:49 |
SO04: Targeted NGS of 22 Mismatch Repair Genes Identifies LS Families – Bente Talseth-Palmer |
12:49 – 12:52 |
SO08: Identification of Novel Causal Genes of Hereditary Colorectal Cancer – Laura Valle |
12:52 – 12:55 |
SO10: Identification of Genetic Biomarkers for Clinical Management of Familial Colorectal Cancer -Mev Dominguez Valentin |
12:55 – 12:58 |
SO03: Evaluation of a 25-Gene Panel in Patients with Suspected Lynch Syndrome: Preliminary Results from the FAMOSA Study – Ariadna Sánchez García |
12:58 – 13:01 |
SO09: Elucidating the Molecular Basis of MSH2-Deficient Tumours in Lynch Syndrome Suspected Patients – Marta Pineda |
13:01 – 13:30 |
Lunch Break |
13:30 – 15:00 |
Registries and Guidelines
Chairs: Rolf Sijmons, Pål Møller, Maurizio Genuardi |
13:30 – 13:45 |
Carriers of Path_MMR Variants: Penetrance, Expressivity and Survival – Pål Møller |
13:45 – 14:00 |
Health Economic Principles – Ian Frayling |
14:00 – 14:15 |
In Vitro Testing – Moni Morak, Elke Holinski |
14:15 – 14:30 |
Potential of International Mismatch Repair Consortium (IMRC) Collaboration – Aung Ko Win |
14:30 – 14:45 |
LOVD and Big Data Management – John Paul Plazzer, Finlay Macrae |
14:45 – 14:53 |
OR02: The LynCE study (The pilot): An assesment of endometrial cancer progression markers in Lynch syndrome – Angel Alonso Sanchez |
14:53 -15:01 |
OR07: Age Stratified Surveillance Strategies Lynch Syndrome-Associated Cancer According to Mismatch Repair Mutation – Neil Ryan |
15:01 – 15:30 |
Discussion: Pathway for Inclusion of Lacking Variant and Mutation Information into the LOVD – Finlay Macrae, Pål Møller |
15:30 – 16:00 |
Coffee Break |
16:00 – 18:05 |
Surgery, Endoscopy and Miscellaneous
Chairs: Jukka Pekka Mecklin, Gabriel Capella, Finlay Macrae |
16:00 – 16:15 |
TaTME for Ileoanal Pouch Surgery in FAP – Potential Short and Longterm Benefits – Antonino Spinelli |
16:15 – 16:30 |
Surgical Strategies for Pouch Surgery: Can We Improve? – Gabriela Möslein |
16:30 – 16:33 |
SO31: Do we Still Need Surgery for Treating Small Bowel Polyps in Peutz-Jeghers Syndrome? A 13-Years Follow-up Cohort – Elia Samaha |
16:33 – 16:36 |
SO33: Assessment of MUTYH Associated Polyposis (MAP) Phenotype in Order to Refine Testing Guidelines – Kate Simon |
16:36 – 16:44 |
OR11: Risk Factors for the Presence of Pathogenic APC and Biallelic MUTYH Mutations in Patients with Multiple Adenomas – Maartje Nielson |
16:44 – 16:47 |
SO30: Compliance and Impact of Colonoscopy in Familial Adenomatous Polyposis and MYH-Associated Polyposis – Carmen Guillén-Ponce |
16:47 – 16:50 |
SO36: Incidence of Colonic Neoplasia in Patients with Serrated Polyposis Syndrome who Undergo Endoscopic Surveillance: a Multicenter Study – Sabela Carballal |
16:50 – 16:53 |
SO34: A Reassessment Colonoscopy Increases the Diagnostic Yield for Serrated Polyposis Syndrome in a Faecal Immunochemical Test (FIT)-Based Colorectal Cancer Screening Population – Maria Pellisé |
16:53 – 16:56 |
SO35: DNA-Diagnostics of Familial Adenomatous Polyposis and Peutz-Jeghers Syndrome Among Russian Patients – Natalia Pospekhova |
16:56 – 16:59 |
SO01: Germline Mutations in MMR Genes Among Russian Patients with Lynch Syndrome – Alexey Tsukanov |
16:59 – 17:02 |
SO06: Impact of an Optimized Colonoscopic Screening Program for Patient with Lynch Syndrome. Four Years Results of a Specialized French Network – Elia Samaha |
17:02 – 17:10 |
OR12: Chromocolonoscopy with Indigo Carmine Facilitates High Adenoma Detection in Lynch Syndrome Patients – Robert Hüneburg |
17:10 – 17:18 |
OR05: Non-Polypous Colorectal Cancer – a Distinct Tumour Type in Lynch Syndrome? – Aysel Ahadova |
17:18 – 17:21 |
SO11: Endoscopic Surveillance of the Upper Gastrointestinal Tract in Lynch Syndrome Patients – Robert Hüneburg |
17:21 – 17:24 |
SO02: DNA Mismatch Repair Genes Deficiency is a Frequent Phenomenon in Small Intestine Adenocarcinoma – Adriana Sanchez Garcia |
17:24 – 17:27 |
SO22: Colon Polyps Prevention and Associated Gut Microbiota Changes in a Colorectal Cancer Animal Model fed with Functional Meat Foods Containing Prebiotics – Felipe Lombó |
17:27 – 17:35 |
OR06: DiagMMR: Functional Lynch Syndrome Carrier Testing from Skin – Minttu Kansikas |
17:35 – 17:43 |
OR01: Universal Screening of Colorectal Cancers for Lynch Syndrome by Reflex Immunohistochemistry – a Single Centre 9 Year Experience – Eanna Ryan |
17:43 – 17:46 |
SO05: Selective and Universal Screening Strategies for Lynch Syndrome: a Perspective from The Royal Marsden Hospital – Bianca Desouza |
17:46 – 17:49 |
SO29: Screening of 274 Familial Colorectal Cancer Patients Using a Multi-Gene Panel – Wenche Sjursen |
17:49 – 17:57 |
OR10: Technological Innovation in Hereditary Cancer Risk Assessment – Anju Kulkarni |
17:57 – 18:05 |
OR08: Young Adult Colorectal Cancer Incidence Trends in Europe: An Important Clinical and Research Opportunity for the European Hereditary Tumour Group – Thomas Weber |